Legend Biotech
LEGN
61 hedge funds and large institutions have $717M invested in Legend Biotech in 2020 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 16 increasing their positions, 16 reducing their positions, and 9 closing their positions.
122% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 9
22% more funds holding
Funds holding: 50 → 61 (+11)
0.37% more ownership
Funds ownership: 9.27% → 9.64% (+0.37%)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
0% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 16
5% less capital invested
Capital invested by funds: $753M → $717M (-$35.9M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$22.5M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
+$12.4M |
| 3 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$12M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
+$7.85M |
| 5 |
AA
ALPS Advisors
Denver,
Colorado
|
+$6.87M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
-$16.6M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$13.2M |
| 3 |
TAMH
Taikang Asset Management (HK)
Hong Kong
|
-$8.15M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$7.98M |
| 5 |
MICM
Matthews International Capital Management
San Francisco,
California
|
-$5.57M |
LEGN Hedge Fund Activity: Q4 2020 in Review
61 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in Legend Biotech (LEGN) for Q4 2020, worth a combined $717M — down 4.8% from $753M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new LEGN positions and 9 closed out — a net gain of 11 holders — while 16 added to existing stakes and 16 trimmed.
The largest buyer was Federated Hermes, adding an estimated $22.5M. The largest seller was Vivo Capital, cutting an estimated $16.6M.
- 61 institutional investors held Legend Biotech (LEGN) as of Q4 2020, up from 50 in Q3 2020.
- Funds reported $717M of Legend Biotech stock for Q4 2020, down 4.8% quarter-over-quarter.
- 20 funds opened new Legend Biotech positions in Q4 2020 and 9 closed out, a net change of +11 holders.
- The largest Legend Biotech buyer in Q4 2020 was Federated Hermes, an estimated $22.5M added.
- The largest Legend Biotech seller in Q4 2020 was Vivo Capital, an estimated $16.6M sold.
Based on aggregated 13F filings for Q4 2020.